Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + PD-1 + Bevacizumab + XELOX in mCRC
NCT06858969Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tucidinostat in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 24 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06858969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858969.